rituximab,polatuzumab vedotin
roche
['lymsm', 'polarix']
re comment from i suspect patient population (clinical trial vs non-trial) may be driving some of the weaker effects of interim ctdna in the polarix trial. would be interested to see stratified on dti. #ash22 #lymsm
Statistician & #lymphoma researcher at Mayo Clinic. #lymsm. Working dad of 3.  Occasional gravel cyclist, love the woods.  Tweets mine.  He/him/his